Testosterone Science

Research Summaries

Beyond Libido: The Multifaceted Role of Testosterone in Women

Citation

Beyond libido: the multifaceted role of testosterone in women

Hernandez BS, Covarrubias A, Perez-Grego PG, et al.

Sex Med Rev. 2026;14(4). Published September 30, 2026.

PMID: 42867946 DOI: 10.1093/sxmrev/qeag072

Study at a Glance

Design
Narrative review
Population
Women across reproductive stages, including after natural or surgical menopause. The authors reported no combined sample size or age range.
Evidence grading
Qualitative synthesis without a reported formal certainty rating or pooled primary endpoint (Hernandez 2026).

Question Addressed

Where do women produce testosterone, and how does it act in different tissues over the lifespan? The review examines how closely blood measurements reflect these actions and what they can tell clinicians about health and symptoms (Hernandez 2026).

Plain Language Summary

Women continue to produce testosterone after menopause. The ovaries make it directly, and tissues such as skin and fat can make it from hormones released by the adrenal glands. Some tissues also convert testosterone to estrogen. A blood test therefore gives only a partial picture of what happens in bone, muscle, the brain, or the reproductive tract [3].

The clearest evidence for treatment concerns postmenopausal women whose persistent loss of sexual desire causes distress. Across trials, women receiving testosterone reported about 1 additional satisfying sexual event per month compared with the comparison groups. Evidence for using testosterone to preserve memory, strengthen bones, or prevent cardiovascular disease remains insufficient [2,4,5].

Methods

3 reviewers independently screened articles using predefined criteria. They grouped evidence by study design, population, reproductive stage, and hormone assay. They used systematic reviews to locate primary studies and provide context. Eligibility focused on endogenous testosterone and excluded supplementation-only studies, abnormal androgen physiology, case reports, letters, and non-English publications (Hernandez 2026).

Key Findings

  • Ovarian function. Ovarian veins contain more testosterone than peripheral blood after menopause, consistent with continued ovarian secretion. Removal of the ovaries was associated with approximately 50% lower testosterone in the evidence cited (Hernandez 2026).
  • Bone and muscle. In 2,198 women aged 40 to 60 years, higher circulating testosterone was associated with greater lumbar spine bone density. Cross-sectional studies generally found no consistent relationship with muscle mass or strength, although cultured muscle cells responded to testosterone (Hernandez 2026).
  • Metabolic and cardiovascular health. Higher free testosterone was associated with greater insulin resistance after menopause in 1 comparison. Cardiovascular findings varied by outcome. Higher concentrations were associated with fewer major cardiovascular events in an older cohort, yet greater arterial plaque burden in a subgroup with existing coronary calcium (Hernandez 2026).
  • Brain and mood. Small experiments found short-term changes on particular spatial memory tasks. Whether naturally occurring hormone differences predict cognitive decline, or treatment improves everyday cognition or mood, remains uncertain (Hernandez 2026, Islam 2019).
  • Sexual and reproductive physiology. Androgen signaling contributes to ovarian follicle development and genital tissue function. The review also describes possible roles in pelvic floor integrity and immunity. Evidence connecting these mechanisms to fertility, continence, or other clinical outcomes remains limited (Hernandez 2026).

Limitations and Strengths Affecting Interpretation

Strengths

  • 3 reviewers independently screened studies against predefined criteria, reducing reliance on any 1 reviewer’s judgment (Hernandez 2026).
  • The review considers assay methods alongside reproductive stage, which helps explain differences between studies of circulating testosterone (Hernandez 2026).
  • The authors bring tissue experiments and human studies together, allowing readers to trace where evidence for a mechanism extends to measured outcomes in women (Hernandez 2026).

Limitations

  • Study design. The review did not formally assess risk of bias or pool estimates. Cross-sectional findings cannot establish whether testosterone levels preceded changes in health or symptoms (Hernandez 2026).
  • Measurement. Assays differ in sensitivity at the low concentrations typical in women. Age, reproductive stage, and binding proteins also complicate comparisons (Davis 2019, Hernandez 2026).
  • Treatment evidence. Small samples for nonsexual outcomes and limited long-term safety data restrict conclusions about preventive use (Davis 2019, Islam 2019).

Read this review as an account of where endogenous testosterone acts. Decisions about prescribing for a particular symptom require trials that measure that outcome in specified populations (Hernandez 2026, Davis 2019).

Authors’ Conclusions

The authors conclude that testosterone contributes to multiple aspects of women’s physiology throughout life. They call for standardized measurement and studies that can determine when differences in endogenous concentrations have clinical consequences (Hernandez 2026).

Commentary

A useful contribution of this review is its explanation of why blood and tissue measurements can diverge. Ovarian secretion, local conversion of adrenal precursors, and conversion to estradiol each influence tissue exposure. These processes help explain why clinicians cannot infer an individual woman’s sexual symptoms from a testosterone concentration (Hernandez 2026, Parish 2021).

Natural and surgical menopause illustrate the importance of clinical history. The ovaries continue to secrete testosterone after natural menopause, whereas removing both ovaries eliminates that source. Adrenal precursors can still be converted to testosterone in peripheral tissues. Thus, 2 women of the same age may have different circulating concentrations and different patterns of tissue exposure. Ovarian status matters when interpreting a study that groups all postmenopausal participants together (Hernandez 2026).

Randomized evidence gives the clearest estimate of treatment benefit for sexual symptoms. A meta-analysis of 36 trials with 8,480 participants found that postmenopausal women reported a mean of 0.85 additional satisfying sexual events per month with testosterone (95% CI 0.52 to 1.18). Sexual distress also improved, with a standardized mean difference of −0.27 (95% CI −0.36 to −0.17) (Islam 2019).

The average increase in satisfying sexual events describes only 1 aspect of the treatment response. For a woman seeking care because low desire causes distress, a change in how she feels about her sexual life may matter more to her than the number of events she records. The trials measured desire and distress separately, giving clinicians a basis for asking about both when assessing response (Islam 2019, Parish 2021).

For a patient distressed by persistent low desire, guidance supports assessing physical, psychological, medication-related, and relationship factors. The global consensus supports testosterone for postmenopausal women with diagnosed hypoactive sexual desire disorder. If treatment is appropriate, the clinical guideline favors transdermal dosing and monitoring to keep concentrations within the physiologic premenopausal range (Davis 2019, Parish 2021).

Blood testing serves a different purpose once treatment is under consideration. A baseline total testosterone measurement gives the clinician a point of comparison. Repeat measurement during treatment can identify concentrations above the physiologic range even when symptoms have improved. The decision about benefit still depends on what the patient reports about desire and distress (Davis 2019, Parish 2021).

Hip fracture recovery illustrates why the choice of endpoint matters. The review highlights a favorable secondary physical performance score. In the underlying trial of 129 women, adding testosterone to supervised exercise changed the 6-minute walking distance by only 2.2 m more than placebo at 24 weeks (95% CI −21.2 to 25.5 m). The primary outcome therefore leaves the added mobility benefit uncertain (Binder 2025, Hernandez 2026).

The hip fracture findings also show why results from different mobility tests can diverge. The performance battery assesses brief tasks such as standing from a chair and maintaining balance. The walking test asks how far a participant can travel in 6 minutes. A favorable score on the shorter tasks can justify further study of those abilities, while the wide confidence interval for walking distance leaves the effect on sustained walking uncertain (Binder 2025).

This review provides a physiologic basis for understanding how testosterone may influence multiple tissues in women, while the clinical significance of many of these mechanisms remains uncertain (Hernandez 2026). In practice, the strongest evidence supports considering transdermal testosterone for postmenopausal women with persistent, distressing low sexual desire after a comprehensive assessment of contributing factors, with follow-up of symptom response and testosterone concentrations (Davis 2019, Parish 2021). Extending treatment to prevent bone loss, cognitive decline, or cardiovascular disease requires trials demonstrating benefits and acceptable safety in the populations being treated (Davis 2019, Islam 2019).

References

1. Binder EF, Bartley JM, Berry SD, Doré PM, Fisher SR, Fortinsky RH, et al. Combining exercise training and testosterone therapy in older women after hip fracture: the STEP-HI randomized clinical trial. JAMA Netw Open. 2025;8(5):e2510512.

| PMID

Supporting quote: “Adding testosterone therapy to exercise may not provide further benefits for long-distance mobility.”

2. Davis SR, Baber R, Panay N, Bitzer J, Cerdas Perez S, Islam RM, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660–4666.

| PMID

Supporting quote: “The only evidence-based indication for testosterone for women is for HSDD.”

3. Hernandez BS, Covarrubias A, Perez-Grego PG, Coady PJ, Walia A, Casperson K, Newson L, Lyon G, Khera M. Beyond libido: the multifaceted role of testosterone in women. Sex Med Rev. 2026;14(4):qeag072.

| PMID

Supporting quote: “Endogenous testosterone in women arises from ovarian, adrenal, neural, and peripheral conversion pathways and persists after menopause.”

4. Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766.

| PMID

Supporting quote: “satisfactory sexual event frequency (mean difference 0·85, 95% CI 0·52 to 1·18)”

5. Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, et al. International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. Climacteric. 2021;24(6):533–550.

| PMID

Supporting quote: “A total testosterone level should not be used to diagnose HSDD, but as a baseline for monitoring.”

Study at a Glance

  • Design. Narrative review of experimental, observational, and clinical research.
  • Sources and dates. PubMed and Scopus, January 1974 through December 2025.

All Research Summaries

Post a Comment or Question

Shared Decision Making

Bring the Evidence to Your Next Consultation

Use our patient resources and questionnaires to prepare questions about symptoms, testing and treatment options for your doctor.